Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 4/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | ACP1 | P24666 | 5/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3466546 | 1.00 | EED (0.56) | EEDCHRNB2CHRNA4KMT2AHRH4 | |
| Hydrochloric Acid SCHEMBL7377970 | 0.89 | SLC6A2 (0.43) | EEDHRH4HRH3HTR1ASLC6A2 | |
| SCHEMBL27599568 | 0.84 | KMT2A (0.49) | EEDCHRNB2CHRNA4KMT2AHRH4 | |
| Hydrochloric Acid SCHEMBL1475436 | 0.83 | KMT2A (0.48) | EEDCHRNB2CHRNA4KMT2AHRH4 | |
| SCHEMBL20181234 | 0.83 | TAAR1 (0.42) | EEDKMT2AHTR1ASLC6A2ATM | |
| Hydrochloric Acid SCHEMBL23830448 | 0.81 | IDO1 (0.41) | EEDKMT2AHTR1ASLC6A2ATM | |
| SCHEMBL13272386 | 0.81 | ATM (0.50) | EEDKMT2AATMSLC6A4 | |
| SCHEMBL11633199 | 0.81 | EED (0.56) | EEDCHRNB2CHRNA4KMT2AHRH4 | |
| SCHEMBL28517671 | 0.81 | EED (0.56) | EEDCHRNB2CHRNA4KMT2AHRH4 | |
| SCHEMBL19908818 | 0.81 | EED (0.56) | EEDCHRNB2CHRNA4KMT2AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010069979-A1 | PYRAN DERIVATIVES AS CCR3 MODULATORS | NYCOMED GMBH (DE) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010069979-A1 | PYRAN DERIVATIVES AS CCR3 MODULATORS | NYCOMED GMBH (DE) | 2010-06-24 | — | — | WO | disclosed |
| US-20040006107-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006107-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR10 | EED 3914/4885CHRNB2 678/4885CHRNA4 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.